LFG
BBIO icon

Larson Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Larson Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,500
Closed -$12K – 1712
2023
Q2 		$12K Buy
+2,500
New +$37.6K ﹤0.01% 878

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Larson Financial Group's BBIO Position: Q1 2026 in Review

Larson Financial Group reduced its BridgeBio Pharma (BBIO) stake by 42% in Q1 2026, selling an estimated $14.6K and leaving 280 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

Larson Financial Group first reported a position in BBIO in Q3 2021 and has held it in 15 quarters since. The position peaked at $36.8K in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Larson Financial Group held 280 shares of BridgeBio Pharma worth $20.8K as of Q1 2026.
  • Larson Financial Group sold 201 BridgeBio Pharma shares in Q1 2026, an estimated $14.6K.
  • BridgeBio Pharma made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #1823 holding.
  • Larson Financial Group first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 15 quarters since.
  • Larson Financial Group's BridgeBio Pharma position peaked at $36.8K in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.